Inflazome Competitors and Similar CompaniesClear all

Inflazome's competitors and similar companies include Theravance Biopharma, SiteOne Therapeutics, CellOxess and Quanterix.

	Inflazome Inflazome engages in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome.	Theravance Biopharma Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses.	SiteOne Therapeutics SiteOne Therapeutics is a company that develops therapeutics for the treatment of hypersensitivity disorders.	CellOxess CellOxess is a company that provides healthcare and biotechnology services.	Quanterix Quanterix is a platform for single molecule analysis that supports clinical diagnostics, drug development, and life science researches.
Founding Date	Founding Date 2016	Founding Date 1996	Founding Date 2014	Founding Date 1990	Founding Date 2007
Type	Type Subsidiary	Type Public	Type Private	Type Private	Type Public
Tags	Tags Healthcare biotech drug development medical diagnostics	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development medical diagnostics	Tags Healthcare biotech drug development medical diagnostics	Tags Healthcare biotech drug development life sciences medical diagnostics
Locations	Locations Dublin 2, IE HQ Brisbane City, AU Cambridge, GB	Locations Dublin, IE HQ San Francisco, US	Locations San Francisco, US HQ Bozeman, US	Locations Ewing Township, US HQ	Locations Billerica, US HQ Baltimore, US Philadelphia, US San Diego, US San Francisco, US Seattle, US
Employees	Employees 156% decrease	Employees 97	Employees 2216% increase	Employees 4	Employees 24840% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 429 m	Valuation ($) 75 m	Valuation ($) N/A	Valuation ($) 506.2 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $107.5m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $138.9m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $73.9m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $107.5m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit $65m (FY, 2025)
Net income	Net income N/A	Net income $105.9m (FY, 2025)	Net income N/A	Net income N/A	Net income ($107.2m) (FY, 2025)
Funding
Total funding raised	Total funding raised $ 17m	Total funding raised $ 55m	Total funding raised $ 17.8m	Total funding raised N/A	Total funding raised $ 96.5m